Biotech

All Articles

Analysts examine Avidity's DMD gain, disclosing nuances in data

.Avidity Biosciences satisfied investors along with period 1/2 records in Duchenne muscular dystroph...

Actinogen's cortisol blocker fails phase 2 depression study

.Actinogen Medical's cortisol blocker has missed out on the primary endpoint of a stage 2 research s...

Bivictrix determines going exclusive only way to take ADC into facility

.Antibody-drug conjugates (ADCs) have been at the center of lots of a billion-dollar biobuck licensi...

TPG tops up funds to $580M for financial investments throughout lifestyle scientific researches

.Resource supervisor TPG, which has actually supported biotechs like Sionna Therapeutics as well as ...

Merck quits period 3 TIGIT trial in lung cancer for impossibility

.Merck &amp Co.'s TIGIT course has endured yet another obstacle. Months after shuttering a period 3 ...

After a tough year, Exscientia folds right into Recursion

.After a year defined through pipe hairstyles, the variation of its own chief executive officer and ...

Cullinan, after $25M package, hands back bispecific to Port

.Cullinan Therapy was actually blown away sufficient with Port BioMed's bispecific invulnerable acti...

A deeper check out Strong Biotech's Ferocious 15

.Within this full week's incident of "The Top Line," our team're diving in to Fierce Biotech's annua...

Lilly faces period 2 failing of tau-targeting med

.The confetti is still soaring from Eli Lilly's celebration commemorating the approval of Alzheimer'...

Biogen CMO Maha Radhakrishnan joins Sofinnova-- Chutes &amp Ladders

.Accept to recently's Chutes &amp Ladders, our roundup of considerable management hirings, shootings...